ex, but in this case PPHM doesn't need to continue to raise cash because
1) It HAS cash reserves (mostly around 50Mil$
2) It has no creditors so no periodic pay downs
3) It has revenue now (which it had NOT at the previous RS)
4) It has announced SUSTAINED PROFITABILITY in (from now) 11 months)
5) It has a commercial product READY for partnering the Exosome based all solid cancer blood test.
6) It has way more potential base value in pipeline (Biomarkers, Bavi, etc)
7) It still holds ALL the PS-Targeting related IP 100% UNENCUMBERED
8) It has a growing network of supporters in PS-targeting
- KOL's
- NCCN, Memorial SK, WISTAR, MOFFIT, etc
- Dr. Wolchok, Dr. Birge and other prominent professors and authors
- Papers and peer reviewed papers
- Several dozen of collaborators (of which several are public now)
- etc
9) It OWNS Avid I, II and in a few months Avid III (6 award winning state-of-the art biosimilar production facilities)
10) It has 70+Mil$ backorders in this growing and exploding market
11) Increased Avid II with 2x2000L reactor for Halo/Roche contract which virtually DOUBLED the Avid II capacity.
12) It cut down on R&D cost of type PIII clinical trials and started PI/II types that partners will take over (which is a good strategy).
13) It has a very low outstanding short-interest
14) Incl. Dart and Ronin the company has currently the HIGHEST % of Inst.Inv/Fund interest EVER
The RS is an indisputable neutral operation, everybody that says otherwise doesn't understand what it is. It is what happens AFTER the RS (good news, bad news, no news, PPS manipulation up, down, etc that will decide what the impact of the RS was). However the SUSTAINABLE PROFIT in 2018 will of course only be split over the NEW amount of shares. And of course the RS must take place first and even the LAST DAY the change remains 50/50.
As for all the Russel nonsense I have read on the board after I was back: PPHM will NOT make the Russel because the market capital is NOT the only parameter. You need to be compliant with the exchanges listing criteria which PPHM under 1$ is not. AIMO
Peregrine Pharmaceuticals the Microsoft of Biotechnology! All In My Opinion. I am not advising anything, nor accusing anyone.
